Phaseline

Companies › Instituto Grifols

Instituto Grifols: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Hematology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AT-III concentrate (ATIII-DAF/DI)
Antithrombin III (plasma-derived concentrate)
SERPINC1Phase 2Antithrombin III Deficiency–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT00319228AT-III concentrate (ATIII-DAF/DI)Phase 2Antithrombin III DeficiencyHematologyDec 2011

Targets

SERPINC1 (1)

Companies with the same targets

Octapharma Sanofi

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.